Results 151 to 160 of about 394,097 (307)

Liquid Metal Nanotransformers for Drug‐Resistant Pan‐Cancer Therapy in Patient‐Derived Organoids

open access: yesAdvanced Science, EarlyView.
Pan‐cancer therapies are severely limited in drug‐resistance patients due to genetic mutations and other factors, resulting in poor therapeutic outcomes and constrained clinical benefit. Liquid metal nanotransformers, a new class of shape‐transformable nanomaterials capable of dramatic morphological changes, offer a promising physical strategy to ...
Xiaojie Yuan   +19 more
wiley   +1 more source

Machine‐Learning Microfluidic Minute‐Scale Microorganism Metrics Monitoring(M6)

open access: yesAdvanced Science, EarlyView.
ABSTRACT On‐site monitoring of microorganisms remains challenging because of low concentrations, strong background interference, and dynamic aerosol diffusion, particularly for aerosol‐transmitted pathogens. Here, we report a rapid detection platform that integrates a Puri‐focusing microfluidic chip, electrochemical impedance spectroscopy (EIS), and ...
Ning Yang   +14 more
wiley   +1 more source

Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR‐NK Therapeutic Strategies

open access: yesAdvanced Science, EarlyView.
This study presents a 3D embedded bioprinting platform that recapitulates key stromal features of the tumor microenvironment using fibroblasts and lung‐derived ECM. The model enables functional assessment of CAR‐NK cells and provides a versatile tool to support the development of next‐generation immunotherapeutic strategies against solid tumors ...
Dahong Kim   +10 more
wiley   +1 more source

Extracellular Vesicle‐Transferred ATP‐Citrate Lyase Induces Monocyte Differentiation Toward Tumor‐Associated Macrophages and Fuels Hepatocellular Carcinoma Progression

open access: yesAdvanced Science, EarlyView.
Hepatocellular carcinoma (HCC)‐derived extracellular vesicles (EVs) enrich the metabolic enzyme ATP‐citrate lyase (ACLY). EV‐transferred ACLY enhances palmitate biosynthesis, increases the S‐palmitoylation and stability of multiple immune checkpoint proteins, augments the cellular immunosuppressive activity, and ultimately accelerates the malignant ...
Zhijun Liu   +11 more
wiley   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou   +12 more
wiley   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Fact sheet for healthcare providers : interpreting Zika MAC-ELISA test results [PDF]

open access: yes
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to authorize the use of the Centers for Disease Control and Prevention (CDC) Zika IgM antibody capture enzyme-linked immunosorbent assay (Zika MAC-ELISA).

core  

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

open access: yesAdvanced Science, EarlyView.
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee   +11 more
wiley   +1 more source

A sensitive enzyme-linked immunosorbent assay for dihydrofolate reductase

open access: yes, 1991
A competitive enzyme-linked immunosorbent assay (ELISA) has been developed for the enzyme, dihydrofolate reductase. The sensitivity of the assay system approximates 3 ng of immunoreactive enzyme protein which is comparable to the sensitivity achieved in ...
Hussain, R, Iqbal, M P
core  

Home - About - Disclaimer - Privacy